Correlation between ELISA and pseudovirion-based neutralisation assay for detecting antibodies against human papillomavirus acquired by natural infection or by vaccination

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Human Vaccines & Immunotherapeutics

• Publication date

  2014-01-02

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4161/hv.27619PMID 24384608PMCID PMC4130265
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Human papillomavirus and cervical cancer.

  2013cited by this paper
• Review: Current knowledge on the role of HPV antibodies after natural infection and vaccination: Implications for monitoring an HPV vaccination programme

  2013cited by this paper
• Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.

  2009cited by this paper
• Human papillomavirus vaccines: WHO position paper.

  2009cited by this paper
• [Production of human papillomavirus type 16 virus-like particles and its immunogenicity].

  2009cited by this paper
• Comparison of the immunogenicity and safety of Cervarix™ and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years

  2009cited by this paper
• [Expression, purification and immunogenicity analysis of HPV type 18 virus-like particles from Escherichia coli].

  2009cited by this paper
• WHO meeting on the standardization of HPV assays and the role of the WHO HPV Laboratory Network in supporting vaccine introduction held on 24-25 January 2008, Geneva, Switzerland.

  2009cited by this paper
• Correlation between direct ELISA, single epitope-based inhibition ELISA and Pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine

  2008cited by this paper
• Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.

  2007cited by this paper
• Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

  2007cited by this paper
• Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.

  2007cited by this paper
• Results of the first WHO international collaborative study on the standardization of the detection of antibodies to human papillomaviruses

  2006cited by this paper
• Chapter 11: HPV vaccines: commercial research & development.

  2006cited by this paper
• [Establishment and application of human papillomavirus type 16 pseudovirions neutralization assay].

  2006cited by this paper
• Immune responses to human papillomavirus.

  2006cited by this paper
• High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

  2006cited by this paper
• Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.

  2005cited by this paper
• Optimization and Validation of a Multiplexed Luminex Assay To Quantify Antibodies to Neutralizing Epitopes on Human Papillomaviruses 6, 11, 16, and 18

  2005cited by this paper
• Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.

  2004influential reference
• Human Papillomavirus and Cervical Cancer

  2003cited by this paper
• Simultaneous Quantitation of Antibodies to Neutralizing Epitopes on Virus-Like Particles for Human Papillomavirus Types 6, 11, 16, and 18 by a Multiplexed Luminex Assay

  2003cited by this paper
• Papillomaviruses and cancer: from basic studies to clinical application

  2002cited by this paper
• Optimization of a Human Papillomavirus-Specific Enzyme-Linked Immunosorbent Assay

  2002cited by this paper
• Identification of Two Cross-Neutralizing Linear Epitopes within the L1 Major Capsid Protein of Human Papillomaviruses

  2002cited by this paper
• Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.

  2001cited by this paper
• Neutralization of human papillomavirus (HPV) pseudovirions: a novel and efficient approach to detect and characterize HPV neutralizing antibodies.

  2000cited by this paper
• Capture-recapture method for estimating misclassification errors: application to the measurement of vaccine efficacy in randomized controlled trials.

  1999cited by this paper

• Immune Responses to Human Papillomavirus After Infection and Vaccination.

  2026cites this paper
• Immunopersistence of one or two doses of an Escherichia coli produced bivalent HPV vaccine

  2025cites this paper
• Evaluation of the safety and immunogenicity of a 9-valent human papillomavirus vaccine produced in Saccharomyces cerevisiae using a heating–chilling process for virus-like particle antigen assembly: a double-blind, randomized, placebo-controlled phase 1 clinical trial

  2025cites this paper
• Assessment of the ability of HPV vaccines to induce neutralizing antibodies based on pseudovirus-based neutralization assay

  2025cites this paper
• Unveiling the seroprevalence of human papillomavirus in Guangdong, China: Implications for vaccination strategies

  2024cites this paper
• Precision and correlation of ED50 and endpoint titer method in measuring HPV vaccine immunogenicity.

  2023cites this paper
• Safety and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus type 6/11 vaccine: A dose-escalation, randomized, double-blind, placebo-controlled phase 1 trial

  2022cites this paper
• Comparison of HPV neutralizing and IgG antibodies in unvaccinated female adolescents.

  2022cites this paper
• Long-Term immunopersistence and safety of the Escherichia coli-produced HPV-16/18 bivalent vaccine in Chinese adolescent girls

  2022cites this paper
• Potent Neutralizing Humanized Antibody With Topical Therapeutic Potential Against HPV18-Related Cervical Cancer

  2021cites this paper
• Naturally acquired HPV antibodies against subsequent homotypic infection: A large-scale prospective cohort study

  2021cites this paper
• Peptide enzyme‐linked immunosorbent assay (pELISA) as a possible alternative to the neutralization test for evaluating the immune response to IBV vaccine

  2021cites this paper
• Age distribution of human papillomavirus infection and neutralizing antibodies in healthy Chinese women aged 18-45 years enrolled in a clinical trial.

  2020cites this paper
• Immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine under different vaccination intervals

  2020cites this paper
• Comparing immunogenicity of the Escherichia coli-produced bivalent human papillomavirus vaccine in females of different ages.

  2020cites this paper
• Novel Production of Bovine Papillomavirus Pseudovirions in Tobacco Plants

  2020cites this paper
• Serum Anti-HPV Antibody Titer as a Marker of Vaccine Effectiveness in Males with Genital Infection

  2020cites this paper
• Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women

  2019cites this paper
• Efficacy, safety, and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine: An interim analysis of a randomized clinical trial.

  2019cites this paper
• Agreement between ELISA and plaque reduction neutralisation assay in Detection of respiratory syncytial virus specific antibodies in a birth Cohort from Kilifi, coastal Kenya.

  2019cites this paper
• Lot-to-lot consistency study of an Escherichia coli-produced bivalent human papillomavirus vaccine in adult women: a randomized trial

  2019cites this paper
• Epitope clustering analysis for vaccine-induced human antibodies in relationship to a panel of murine monoclonal antibodies against HPV16 viral capsid.

  2018cites this paper
• Escherichia coli-derived virus-like particles in vaccine development

  2017cites this paper
• Bacterially expressed human papillomavirus type 6 and 11 bivalent vaccine: Characterization, antigenicity and immunogenicity.

  2017cites this paper
• Candidatos vacunales profilácticos de segunda y tercera generación contra el virus del papiloma humano

  2017cites this paper
• A novel trivalent HPV 16/18/58 vaccine with anti-HPV 16 and 18 neutralizing antibody responses comparable to those induced by the Gardasil quadrivalent vaccine in rhesus macaque model

  2017cites this paper
• Reformulation of a thermostable broadly protective recombinant vaccine against human papilloma virus

  2016cites this paper
• Functional assessment and structural basis of antibody binding to human 2 papillomavirus capsid 3

  2016cites this paper
• Development of a Triple-Color Pseudovirion-Based Assay to Detect Neutralizing Antibodies against Human Papillomavirus

  2016cites this paper
• Functional assessment and structural basis of antibody binding to human papillomavirus capsid

  2016cites this paper
• HPV Prophylactic Vaccination in Males Improves the Clearance of Semen Infection☆

  2015cites this paper
• HPV and cancer 2 Next generation prophylactic human papillomavirus vaccines

  2015cites this paper
• Next generation prophylactic human papillomavirus vaccines.

  2015cites this paper
• Establishment of an in vitro equine papillomavirus type 2 (EcPV2) neutralization assay and a VLP-based vaccine for protection of equids against EcPV2-associated genital tumors.

  2015cites this paper
• Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trial.

  2015cites this paper